Metagenomi Therapeutics (MGX) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 9, 2026, to be held virtually for shareholder participation.

• Shareholders are encouraged to review proxy materials and vote by June 8, 2026, 11:59 p.m. Eastern Time.

Voting matters and shareholder proposals

• Election of two Class II director nominees: Juergen Eckhardt, MD, MBA, and Eric Bjerkholt, MBA, both recommended by the board.

• Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Other business may be addressed as appropriate during the meeting or any adjournment.

Board of directors and corporate governance

• Board recommends both director nominees for election to serve as Class II directors.